Search clinical trials for: Solabegron (GW427353)

Total 9 results

GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

Irritable Bowel Syndrome (IBS)

United States
GlaxoSmithKline

Completed

A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS)

Germany, Australia, France
Velicept Therapeutics, Inc.

Completed

Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects

Healthy Subjects, Overactive Bladder
Velicept Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

Overactive Bladder

United States
Velicept Therapeutics, Inc.

Completed

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (VEL-2001)

Overactive Bladder

United States
Universität Duisburg-Essen

Completed

The Effect of Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome (CarO)

Irritable Bowel Syndrome

Germany
GlaxoSmithKline

Completed

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

Overactive Bladder

United States
GlaxoSmithKline

Completed

Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

Overactive Bladder

Germany, Taiwan, Netherlands, Spain, Australia, Korea, Republic of, Latvia, Argentina, Slovenia, Finland, France, South Africa, Poland, New Zealand
GlaxoSmithKline

Completed

A Two-Part Study to Determine: Best Medication Formulation and Food Effect

Overactive Bladder

United States

3

Subscribe